Interstitial nephritis secondary prevention: Difference between revisions
| Line 4: | Line 4: | ||
== Overview == | == Overview == | ||
The mainstay preventive action is to stay away from reexposure to the offensive agents of the acute episode. Among patients with chronic inflammatory diseases such as Sjogren syndrome, sarcoidosis, or SLE, proper control of the underlying condition is important. | |||
== Secondary Prevention == | == Secondary Prevention == | ||
The | The mainstay preventive action is to stay away from exposure to the offensive agents of the acute episode. If the culprit drug has clearly been identified, then avoiding future use of the medication is recommended, because AIN may recur on re-exposure to the original antigen. Where known cross-reactivity exists, for example between penicillins and cephalosporins, the risk of using a related agent should be carefully weighed against the benefit of using it. If such an agent is used, the patient should be appropriately monitored for any side effects. For patients with chronic inflammatory diseases such as Sjogren syndrome, sarcoidosis, or SLE, proper control of the underlying condition is important. | ||
==References== | ==References== | ||
Revision as of 16:12, 18 July 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:Mohsen Basiri M.D.
Overview
The mainstay preventive action is to stay away from reexposure to the offensive agents of the acute episode. Among patients with chronic inflammatory diseases such as Sjogren syndrome, sarcoidosis, or SLE, proper control of the underlying condition is important.
Secondary Prevention
The mainstay preventive action is to stay away from exposure to the offensive agents of the acute episode. If the culprit drug has clearly been identified, then avoiding future use of the medication is recommended, because AIN may recur on re-exposure to the original antigen. Where known cross-reactivity exists, for example between penicillins and cephalosporins, the risk of using a related agent should be carefully weighed against the benefit of using it. If such an agent is used, the patient should be appropriately monitored for any side effects. For patients with chronic inflammatory diseases such as Sjogren syndrome, sarcoidosis, or SLE, proper control of the underlying condition is important.